Cargando…
Ruthenium(II) Complexes with 2-Phenylimidazo[4,5-f][1,10]phenanthroline Derivatives that Strongly Combat Cisplatin-Resistant Tumor Cells
Cisplatin was the first metal-based therapeutic agent approved for the treatment of human cancers, but its clinical activity is greatly limited by tumor drug resistance. This work utilized the parent complex [Ru(phen)(2)(PIP)](2+) (1) to develop three Ru(II) complexes (2–4) with different positional...
Autores principales: | Zeng, Leli, Chen, Yu, Liu, Jiangping, Huang, Huaiyi, Guan, Ruilin, Ji, Liangnian, Chao, Hui |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4725915/ https://www.ncbi.nlm.nih.gov/pubmed/26763798 http://dx.doi.org/10.1038/srep19449 |
Ejemplares similares
-
5H-Imidazo[4,5-f][1,10]phenanthroline
por: Tong, Shao-Wei, et al.
Publicado: (2012) -
Bis(imidazo[4,5-f][1,10]phenanthroline)dinitratolead(II)
por: Li, Chun-Xiang, et al.
Publicado: (2008) -
1,2-Diphenyl-1H-imidazo[4,5-f][1,10]phenanthroline
por: Rosepriya, S., et al.
Publicado: (2011) -
1H-Imidazo[4,5-f][1,10]phenanthrolin-7-ium perchlorate monohydrate
por: Shen, Su-Mei
Publicado: (2009) -
Tris(1,10-phenanthroline-κ(2)
N,N′)ruthenium(II) bis(perchlorate)
por: Kozlowska, Mariana, et al.
Publicado: (2012)